Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.

Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo Coco F, Arcese W, Amadori S.

Blood. 2019 Aug 8. pii: blood.2018886960. doi: 10.1182/blood.2018886960. [Epub ahead of print]

PMID:
31395600
2.

Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.

Niscola P, Noguera NI, Catalano G, Cupelli L, Fratoni S, Giovannini M, Mazzone C, Neri B, Scaramucci L, Trawinska MM, de Fabritiis P, Abruzzese E.

Acta Oncol. 2019 Jun;58(6):888-890. doi: 10.1080/0284186X.2019.1585943. Epub 2019 Mar 8. No abstract available.

PMID:
30848978
3.

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.

Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, Chierichini A, Di Venanzio M, Sollazzo F, Piedimonte M, Cupelli L, Bruno A, De Angelis G, Delbono L, Niscola P, Perrotti AP, de Fabritiis P, Arcese W; Rome Transplant Network.

Support Care Cancer. 2019 Mar;27(3):793-803. doi: 10.1007/s00520-018-4594-2. Epub 2018 Dec 18. Review.

PMID:
30564934
4.

Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia.

Abruzzese E, de Fabritiis P, Trawinska MM, Niscola P, Apperley JF, Mauro MJ.

Eur J Haematol. 2019 Feb;102(2):197-199. doi: 10.1111/ejh.13192. Epub 2018 Nov 29. No abstract available.

PMID:
30403419
5.

Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm.

Abruzzese E, Trawinska MM, Neri B, Bondanini F, Fratoni S, Tendas A, Scaramucci L, Siniscalchi A, Giovannini M, Palumbo R, de Fabritiis P, Niscola P.

Acta Haematol. 2018;140(4):231-233. doi: 10.1159/000493880. Epub 2018 Nov 1. No abstract available.

PMID:
30384359
6.

Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers.

Barcellini W, Zaninoni A, Fattizzo B, Giannotta JA, Lunghi M, Ferrari A, Leporace AP, Maschio N, Scaramucci L, Cantoni S, Chiurazzi F, Consonni D, Rossi G, De Fabritiis P, Gaidano G, Zanella A, Cortelezzi A.

Am J Hematol. 2018 Sep;93(9):E243-E246. doi: 10.1002/ajh.25212. Epub 2018 Aug 25. No abstract available.

7.

Gender, age and diagnosis effect on self-perceived pain in hematological patients: retrospective analysis of two case series.

Tendas A, Malandruccolo L, Venditti D, Costa A, Volta L, Annibali O, Marchesi F, Saltarelli D, de Fabritiis P, Arcese W, Bondanini F, Niscola P, Palumbo R.

Ann Palliat Med. 2018 Oct;7(4):484-486. doi: 10.21037/apm.2018.04.03. Epub 2018 May 9. No abstract available.

8.

Chronic myeloproliferative disorders: is quality-of-life the new goal?

Abruzzese E, Niscola P, Trawinska MM, de Fabritiis P.

Curr Med Res Opin. 2018 Jul;34(7):1345-1347. doi: 10.1080/03007995.2018.1473245. Epub 2018 Jun 1. No abstract available.

PMID:
29724146
9.

Revisiting Strephosymbolie: The Connection between Interhemispheric Transfer and Developmental Dyslexia.

Daini R, De Fabritiis P, Ginocchio C, Lenti C, Lentini CM, Marzorati D, Lorusso ML.

Brain Sci. 2018 Apr 17;8(4). pii: E67. doi: 10.3390/brainsci8040067.

10.

Is cell therapy the answer for hematological malignancies?

Niscola P, de Fabritiis P.

Expert Opin Biol Ther. 2018 May;18(5):495-497. doi: 10.1080/14712598.2018.1454900. Epub 2018 Mar 27. No abstract available.

PMID:
29557205
11.

Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient.

Niscola P, Neri B, Morino L, de Fabritiis P.

Acta Haematol. 2018;139(1):58-59. doi: 10.1159/000485960. Epub 2018 Jan 17. No abstract available.

12.

Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?

Niscola P, Caravita T, Tatangelo P, Siniscalchi A, de Fabritiis P, Palumbo R.

Blood Res. 2017 Sep;52(3):218-219. doi: 10.5045/br.2017.52.3.218. Epub 2017 Sep 25. No abstract available.

13.

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.

Niscola P, Tendas A, Abruzzese E, Caravita T, Cupelli L, Giovannini M, Scaramucci L, Siniscalchi A, Trawinska MM, de Fabritiis P.

Ann Hematol. 2017 Sep;96(9):1591-1593. doi: 10.1007/s00277-017-3064-0. Epub 2017 Jul 12. No abstract available.

PMID:
28702776
14.

Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.

Abruzzese E, Trawinska MM, Gaspardone A, Morocutti A, de Fabritiis P.

Hematol Rep. 2017 Jun 28;9(2):6944. doi: 10.4081/hr.2017.6944. eCollection 2017 Jun 1.

15.

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Mayer F, Faglioni L, Agabiti N, Fenu S, Buccisano F, Latagliata R, Ricci R, Spiriti MAA, Tatarelli C, Breccia M, Cimino G, Fianchi L, Criscuolo M, Gumenyuk S, Mancini S, Maurillo L, Nobile C, Niscola P, Piccioni AL, Tafuri A, Trapè G, Andriani A, De Fabritiis P, Voso MT, Davoli M, Zini G.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.

16.

Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.

Niscola P, Abruzzese E, Trawinska MM, Palombi M, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Fratoni S, Noguera NI, Catalano G, de Fabritiis P.

Acta Oncol. 2017 Oct;56(10):1331-1333. doi: 10.1080/0284186X.2017.1324215. Epub 2017 May 10. No abstract available.

PMID:
28488914
17.

Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia.

Niscola P, Neri B, Catalano G, Morino L, Giovannini M, Scaramucci L, Fratoni S, Noguera NI, Cordone I, de Fabritiis P.

Acta Oncol. 2017 Aug;56(8):1120-1121. doi: 10.1080/0284186X.2017.1287947. Epub 2017 Feb 17. No abstract available.

PMID:
28406054
18.

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, Tedeschi A, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R.

Haematologica. 2016 Dec;101(12):1544-1552. Epub 2016 Aug 11.

19.

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.

Tendas A, Niscola P, Scaramucci L, Cupelli L, Perrotti AP, de Fabritiis P.

Blood Res. 2016 Jun;51(2):137-8. doi: 10.5045/br.2016.51.2.137. Epub 2016 Jun 23. No abstract available.

20.

Management of pregnant chronic myeloid leukemia patients.

Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M.

Expert Rev Hematol. 2016 Aug;9(8):781-91. doi: 10.1080/17474086.2016.1205479. Epub 2016 Jul 7. Review.

PMID:
27352939
21.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
22.

Primitive "Spindle Cell Variant" (Sarcomatoid Variant) Diffuse Large B-Cell Lymphoma of the Uterine Cervix: Description and Outcome of a Rare Case.

Fratoni S, Abruzzese E, Trawinska MM, Niscola P, de Fabritiis P, Santeusanio G.

Int J Gynecol Pathol. 2016 Nov;35(6):593-597.

PMID:
27167673
23.

Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?

Palombi M, Scaramucci L, Giovannini M, Trawinska MM, Niscola P, de Fabritiis P.

Blood Res. 2016 Mar;51(1):66. doi: 10.5045/br.2016.51.1.66. Epub 2016 Mar 25. No abstract available.

24.

Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy?

Tendas A, Cupelli L, Mauroni MR, Sollazzo F, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano MA, Annibali O, Piedimonte M, Conte E, Marchesi F, Viggiani C, Pignatelli AC, Dentamaro T, de Fabritiis P, Perrotti AP, Arcese W; Quality of Life Working Party of the Rome Transplant Network.

Cancer. 2016 May 1;122(9):1461-2. doi: 10.1002/cncr.29943. Epub 2016 Mar 11. No abstract available.

25.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

26.

Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome?

Niscola P, Cupelli L, Dentamaro T, de Fabritiis P.

Leuk Res. 2016 Mar;42:80-1. doi: 10.1016/j.leukres.2015.12.014. Epub 2016 Jan 4. No abstract available.

PMID:
26790726
27.

CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.

Chiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo AL, Piciocchi A, Elia L, Vitale A, Mauro E, Ferrara F, De Fabritiis P, Luppi M, Ronco F, De Propris MS, Raponi S, Kronnie GT, Vignetti M, Guarini A, Foà R.

Leuk Res. 2016 Feb;41:36-42. doi: 10.1016/j.leukres.2015.11.018. Epub 2015 Dec 23.

PMID:
26754556
28.

Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network.

Tendas A, Cupelli L, Mauroni MR, Sollazzo F, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano M, Annibali O, Piedimonte M, Conte E, Marchesi F, Viggiani C, Pignatelli AC, Dentamaro T, Niscola P, de Fabritiis P, Perrotti AP, Arcese W.

Bone Marrow Transplant. 2016 May;51(5):638-9. doi: 10.1038/bmt.2015.341. Epub 2016 Jan 11. No abstract available.

PMID:
26752143
29.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

30.

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.

Niscola P, Tendas A, Merola R, Orlandi G, Scaramucci L, de Fabritiis P.

Blood Res. 2015 Sep;50(3):181-2. doi: 10.5045/br.2015.50.3.181. Epub 2015 Sep 22. No abstract available.

31.

Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts.

Picardi A, Mengarelli A, Marino M, Gallo E, Benevolo M, Pescarmona E, Cocco R, Fraioli R, Tremante E, Petti MC, De Fabritiis P, Giacomini P.

J Exp Clin Cancer Res. 2015 Sep 11;34:98. doi: 10.1186/s13046-015-0213-y.

32.

Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma.

Niscola P, Siniscalchi A, Tendas A, de Fabritiis P, Caravita T, Efficace F.

Support Care Cancer. 2016 Jan;24(1):9-10. doi: 10.1007/s00520-015-2868-5. Epub 2015 Aug 4. No abstract available.

PMID:
26238628
33.

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.

Niscola P, Tendas A, Scaramucci L, Giovannini M, Fratoni S, de Fabritiis P.

Blood Res. 2015 Jun;50(2):113-4. doi: 10.5045/br.2015.50.2.113. Epub 2015 Jun 25. No abstract available.

34.

Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.

Niscola P, Siniscalchi A, Tendas A, Scaramucci L, Fratoni S, de Fabritiis P, Caravita T.

Ann Hematol. 2015 Oct;94(10):1753-4. doi: 10.1007/s00277-015-2431-y. Epub 2015 Jun 20. No abstract available.

PMID:
26088814
35.

Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need.

Tendas A, Niscola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W; Rome Transplant Network (RTN) Quality of Life Working Party.

Support Care Cancer. 2015 Aug;23(8):2211. doi: 10.1007/s00520-015-2711-z. Epub 2015 Mar 28. No abstract available.

PMID:
25821108
36.

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

Tendas A, Lissia MF, Piccioni D, Tirimbelli L, Scaramucci L, Giovannini M, Dentamaro T, Perrotti A, de Fabritiis P, Niscola P.

Support Care Cancer. 2015 Feb;23(2):303-5. doi: 10.1007/s00520-014-2502-y. Epub 2014 Nov 5. No abstract available.

PMID:
25370894
37.

Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.

Scaramucci L, Giovannini M, Niscola P, Tendas A, Perrotti A, De Fabritiis P.

Blood Transfus. 2014 Oct;12(4):605-7. doi: 10.2450/2014.0246.13. No abstract available.

38.

Caring for terminal patients in haematology: the urgent need of a new research agenda.

Niscola P, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P, Howell DA.

Support Care Cancer. 2015 Jan;23(1):5-7. doi: 10.1007/s00520-014-2489-4. Epub 2014 Oct 24.

PMID:
25341550
39.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A.

Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.

40.

Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.

Niscola P, Tendas A, Cupelli L, Giovannini M, Piccioni D, Scaramucci L, Dentamaro T, Del Poeta G, de Fabritiis P.

Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14. No abstract available.

PMID:
25139255
41.

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.

Niscola P, Tendas A, Scaramucci L, Merola R, Catalano G, de Fabritiis P.

Blood Res. 2014 Jun;49(2):130-7. doi: 10.5045/br.2014.49.2.130. Epub 2014 Jun 25. No abstract available.

42.

Making quality of life assessment a dashboard for patient management.

Tendas A, Niscola P, Scaramucci L, Giovannini M, Dentamaro T, Perrotti AP, de Fabritiis P.

Support Care Cancer. 2014 Sep;22(9):2311-2. doi: 10.1007/s00520-014-2342-9. Epub 2014 Jul 4. No abstract available.

PMID:
24993396
43.

Fibrin glue therapy for severe hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Tirindelli MC, Flammia GP, Bove P, Cerretti R, Cudillo L, De Angelis G, Picardi A, Annibali O, Nobile C, Cerchiara E, Dentamaro T, De Fabritiis P, Lanti A, Ferraro AS, Sergi F, Di Piazza F, Avvisati G, Arcese W; Rome Transplant Network.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1612-7. doi: 10.1016/j.bbmt.2014.06.018. Epub 2014 Jun 20.

44.

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G.

Ann Hematol. 2014 Oct;93(10):1765-74. doi: 10.1007/s00277-014-2117-x. Epub 2014 Jun 13.

PMID:
24923451
45.

Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.

Scaramucci L, Giovannini M, Niscola P, Tendas A, Perrotti A, De Fabritiis P.

Blood Transfus. 2014 Mar 21:1-3. doi: 10.2450/2014.0246-13. [Epub ahead of print] No abstract available.

46.

Tyrosine kinase inhibitors and pregnancy.

Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P.

Mediterr J Hematol Infect Dis. 2014 Apr 7;6(1):e2014028. doi: 10.4084/MJHID.2014.028. eCollection 2014. Review.

47.

Pure erythroid leukemia in advanced breast cancer.

Niscola P, Tendas A, Minelli M, Perrotti A, de Fabritiis P, Del Poeta G.

Blood Res. 2014 Mar;49(1):69-72. doi: 10.5045/br.2014.49.1.69. Epub 2014 Mar 24. No abstract available.

48.

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.

Niscola P, Tendas A, Scaramucci L, Giovannini M, Piccioni D, de Fabritiis P.

Blood Res. 2014 Mar;49(1):65-6. doi: 10.5045/br.2014.49.1.65. Epub 2014 Mar 24. No abstract available.

49.

Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.

Tendas A, Cupelli L, Siniscalchi A, Scaramucci L, Giovannini M, Dentamaro T, Perrotti A, Caravita T, de Fabritiis P, Niscola P.

Mediterr J Hematol Infect Dis. 2014 Feb 16;6(1):e2014020. doi: 10.4084/MJHID.2014.020. eCollection 2014.

50.

Motor disability, clinical complications, quality of life, and survival in patients with cancer: a plausible scenario.

Tendas A, Niscola P, Scaramucci L, Giovannini M, Dentamaro T, Perrotti AP, de Fabritiis P.

Support Care Cancer. 2014 Oct;22(10):2603-4. No abstract available.

PMID:
24659217

Supplemental Content

Loading ...
Support Center